[Combined group A streptococcus preparation (sapylin) and cisplatin for malignant peritoneal effusion].
OBJECTIVE
To evaluate the effect of Group A streptococcus preparation (sapylin) combined with cisplatin on the malignant peritoneal effusion in patients with advanced cancer.


METHODS
Sixty advanced cancer patients with large amount of peritoneal effusion were divided into two groups: sapylin + cisplatin (DDP) group (30 patients) and control group (DDP alone, 30 cases). All the chemotherapeutic agents were injected intraperitoneally through a catheter.


RESULTS
In sapylin + cisplatin(DDP) group, 11 (36.7%) patients showed CR and 16 (53.3%) PR. The overall response rate (CR + PR) was 90.0%. Those of DDP alone group were 16.7% and 46.7%, the overall response rate was 63.3%. The main adverse effects were fever, nausea, and vomiting.


CONCLUSIONS
Combined Group A streptococcus preparation (sapylin) and cisplatin is more effective than cisplatin alone for the malignant peritoneal effusion in patients with advanced cancer, and the adverse effects are tolerable.
Pan
Jing
J
Department of Comprehensive Care, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. helen6325@sina.com
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001202:Ascitic Fluid / Q000473:pathology*; D001426:Bacterial Proteins / Q000008:administration & dosage*; D001688:Biological Products / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy; D013297:Streptococcus pyogenes / Q000737:chemistry*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D001688:Biological Products; D007155:Immunologic Factors; C569879:streptococcal preparation 722; D002945:Cisplatin